ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

In Brief: Cancer Research Institute to Support AIDS Grants, With Maximum $70,000 Each; Deadline Is Oct. 1

July 15, 1983

Big Community Programs Under Way In Detroit, N.M.; Others Near OK

January 14, 1977

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

November 20, 1992

Bisphosphonates May Reduce Recurrent Breast Cancer

December 25, 2009

In Brief: NIH Reviewers, Advisors To Get Increase In Honoraria; Price Leaving NCI for Maryland

March 14, 1980

Tough Year Seen for Cooperative Groups; Priority Payment Questioned

December 2, 1988